BrainCheck

Name: BrainCheck
Brand: BrainCheck
Rating: 5 (1 reviews)

BrainCheck is a digital cognitive-care platform that combines population analytics, screening, and a workflow-oriented system that includes a 15-minute FDA-registered Class II digital cognitive assessment covering five domains, interpretation support, and care-planning/follow-up for clinical use.

Est 2014|Valuation $75M|42 Ref Customers

LinkedIn 12K|Website|FTEs 69|HQ Austin, Texas, US

Published Oct 13, 2026

01Common complaints

- Scenarios where alternatives may be more suitable - Organizations primarily focused on research or clinical-trial cognitive measurement rather than clinical care planning workflows - A research-oriented vendor may be a better fit for study-specific endpoints. - Organizations that require a large volume of independent reviews on public review platforms as a procurement requirement - This product has limited third-party review volume on major review sites. - Organizations that require fully public, detailed pricing to complete rapid ROI modeling - The vendor’s publicly visible pricing details are limited and procurement may require direct engagement. - Environments that cannot tolerate documentation or workflows outside the EHR - If care plans or reports cannot be integrated into the primary medical record in a usable way, staff may prefer other approaches. - Diligence checkpoints and requests - Request vendor-provided evidence of HITRUST and TX-RAMP scope (environment, dates, and any exclusions). - Confirm FDA Class II status details and the vendor-described intended use language for BrainCheck Assess to avoid diagnostic overreach. - Validate EHR integration depth (orders, results ingestion, discrete fields vs documents, in-basket routing, audit trail). - Publicly observable limitations and gaps - Review scarcity - Major review platforms had limited sample sizes for this product at the time of the research, which limits independent "voice of customer" evidence. - Security transparency gaps - SOC 2 and ISO 27001 were not clearly documented publicly in the accessible sources; data residency options were also not clearly documented. - Regulatory/clinical limitations - The assessment component is described by the vendor as an assessment aid and not a standalone diagnostic tool; clinicians should interpret scores in clinical context. - Integration limitations - Feature availability may depend on the depth of EHR integration implemented at each site. Integration effort and maintenance burden can vary by EHR and site configuration. - Roadmap visibility - The vendor references frequent feature releases, but a public roadmap with firm dates was not found in accessible materials.

02Why they buy

- Differentiation described by the vendor - The vendor describes the product as a platform spanning analytics through care planning and provides a regulated (Class II) digital cognitive assessment component (BrainCheck Assess). - The vendor reports a large dataset of assessments and a frequent release cadence; these are vendor-reported metrics and should be validated. - What is validated vs not in accessible sources - Validated/confirmable in accessible sources - The FDA device database includes an entry for BrainCheck Assess identifying it as a computerized cognitive assessment aid (device listing available in public device registries). - The vendor’s security and compliance page documents HITRUST and TX-RAMP claims, which organizations should validate via direct evidence requests. - Vendor claims requiring further validation - The vendor-reported dataset size and release cadence are not independently audited in the accessible materials and should be verified if material to procurement.

03Field reports

Customer Testimonials

- Important limitation on review data quality - Mainstream SaaS review sites appear to have limited product-specific review volume for this product. - Review platforms - G2 - The vendor’s G2 listing indicated there were not enough reviews to provide buying insight at the time of the crawl. - Capterra - Capterra showed a very small review sample; this is too small a sample to generalize. - Gartner Peer Insights - No confirmed product review page was found in the accessible crawl; search results returned general pages rather than a product listing. - Community/social discussion (more candid but not structured) - Selected forum posts indicate awareness of the product among clinicians and patients; comments referenced use of BrainCheck and noted concerns such as technical literacy, frustration, and test anxiety. These community references are anecdotal and not systematically representative. - Vendor testimonials (marketing; not independently verified) - Examples on the vendor site include claims about improved workflow efficiency versus paper testing and EHR integration. These are vendor claims and should be validated in context. - What customers cite as reasons to choose BrainCheck (derived from vendor claims and limited community context) - Workflow efficiency relative to paper testing - Standardization and longitudinal tracking - EHR integration (vendor cites common EHRs, including Epic and athenahealth) - Reimbursement guidance and decision-support reporting - Why some customers might leave (inferred in absence of broad churn data) - If billing/reimbursement workflows do not produce expected revenue - If patient experience (remote testing usability, tech friction) reduces completion rates - If integration is more complex than expected in a given EHR environment - If care plans are stored outside the primary medical record and create additional lookup burden

Vendor-published case studies exist

The vendor publishes case study PDFs and example deployments; these are vendor-supplied materials.

Critical evaluation of case-study evidence

Metrics and outcomes in vendor case studies should be treated as vendor-provided evidence unless methodology, sample size, baseline data, and potential confounders are described or a third party corroborates outcomes. If a case study claims improved efficiency or revenue, organizations should request de-identified billing reports, denial rates, payer mix, and CPT code utilization context.

Clinical validation claims and supporting literature

The vendor cites correlations with established measures (for example MoCA) and provides whitepapers reporting diagnostic performance metrics (for example sensitivity and specificity) for screening studies. Whitepapers can be informative but are not equivalent to independent peer-reviewed replication; the underlying peer-reviewed publications should be reviewed for population, setting, and potential bias.

04Best fit

- Organization sizes (practical ranges) - Small practices - The vendor describes a self-sign-up pathway for smaller practices that meet a vendor-defined patient-volume threshold; vendor pricing and exact limits should be confirmed. - Mid-market / enterprise health systems - The vendor markets population analytics and EHR integration pathways that suggest suitability for health-system scale deployments. - Industries and verticals where adoption is most relevant - Neurology, geriatrics, psychiatry, and primary care (explicitly targeted by vendor materials) - Academic and research institutions have been cited in vendor materials or collaborations; these may represent research partnerships rather than operational deployments. - Roles and personas - Decision makers - Clinical leadership (e.g., neurology, geriatrics), population health leaders, and IT/EHR integration and compliance/security leadership - End users - Clinicians interpreting results, medical assistants or staff administering tests, and patients completing assessments (including remote completion) - Pain points the product addresses - Under-identification of cognitive impairment in routine care - Administrative burdens of paper-based cognitive testing (time requirements, subjective scoring, workflow interruptions) - Need for longitudinal monitoring and structured care planning - Qualification criteria (good fit) - Practices that routinely screen older adults and want standardized digital testing and repeat measures - Organizations prepared to operationalize EHR integration and documentation workflows - Teams seeking a vendor that reports healthcare-focused security certifications - Deal disqualifiers (poor fit) - Organizations requiring extensive independent peer-reviewed validation and a large body of third-party customer reviews as procurement preconditions - Organizations unable to support integration work or staff training for new assessment workflows - Use cases requiring publicly documented SOC 2/ISO evidence and explicit data residency controls where those cannot be provided via vendor documentation or NDA

05The pitch

What the product does (core value proposition in objective terms)

- BrainCheck is a digital cognitive-care platform that combines population analytics, cognitive screening/assessment, interpretation support, and care planning/follow-up into a single, workflow-oriented system for clinical use. - The vendor frames the platform as providing an integrated cognitive-care workflow covering population analytics → screening → assessment → interpretation → care planning → follow-up. - A key product module, BrainCheck Assess™, is described by the vendor as a short digital cognitive assessment covering multiple cognitive domains; this module is the platform’s only FDA-registered Class II component.

Target market and market positioning

- Primary audience: neurologists, psychiatrists, primary care providers, geriatric practices, health systems, and clinical researchers. - Positioning themes cited by the vendor include: - Replacing paper tests with standardized digital testing and longitudinal monitoring - Emphasis on integrating with clinical EHR workflows (vendor calls out integrations with major EHRs) - Supporting scale for proactive cognitive care via population analytics and patient registries

Get a comprehensive analysis of BrainCheck including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →